Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $51.22 +0.02 (0.04%) 6:34 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNY 51.20 +0.77(1.53%)
Will SNY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
Other News for SNY
Sanofi call volume above normal and directionally bullish
Sanofi’s Dupixent: A New Era in COPD Treatment
Merck RSV therapy succeeds in infants in challenge to Sanofi, Astra
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife